Stockscreener 앱 받기
26.71
0.19%
0.05
시간 외 거래:
26.69
-0.02
-0.07%
전일 마감가:
$26.66
열려 있는:
$26.67
하루 거래량:
5.32M
Relative Volume:
2.19
시가총액:
$1.42B
수익:
$75.04M
순이익/손실:
$-167.18M
주가수익비율:
-8.3555
EPS:
-3.1967
순현금흐름:
$-168.39M
1주 성능:
+38.83%
1개월 성능:
+34.22%
6개월 성능:
+143.04%
1년 성능:
+103.89%
1일 변동 폭
$26.66
$26.72
1주일 범위
$26.63
$26.76
52주 변동 폭
$9.83
$26.76
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
명칭
Kalvista Pharmaceuticals Inc
전화
(857) 999-0075
주소
200 CROSSING BOULEVARD, FRAMINGHAM, MA
Compare KALV vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
26.71 | 1.42B | 75.04M | -167.18M | -168.39M | -3.1967 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-09 | 재확인 | Needham | Buy |
| 2026-01-06 | 재확인 | Needham | Buy |
| 2025-01-31 | 개시 | JMP Securities | Mkt Outperform |
| 2025-01-07 | 개시 | TD Cowen | Buy |
| 2024-12-18 | 개시 | BofA Securities | Buy |
| 2020-06-15 | 개시 | H.C. Wainwright | Buy |
| 2019-07-29 | 개시 | SVB Leerink | Outperform |
| 2019-03-20 | 개시 | Needham | Buy |
| 2018-10-30 | 개시 | Jefferies | Buy |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-08-31 | 개시 | BTIG Research | Buy |
모두보기
Kalvista Pharmaceuticals Inc 주식(KALV)의 최신 뉴스
Chiesi Farmaceutici (NASDAQ: KALV) offers $27.00 per share to buy KalVista - Stock Titan
KalVista climbs as Italy’s Chiesi agrees to acquire in $1.9B deal - MSN
Are XOMA, RMAX, KALV Obtaining Fair Deals for their Shareholders? - Sahm
Chiesi to buy KalVista Pharmaceuticals for $1.9 billion - MSN
Avoiding Lag: Real-Time Signals in (KALV) Movement - Stock Traders Daily
HC Wainwright & Co. downgrades KalVista Pharmaceuticals (KALV) - MSN
KalVista Pharmaceuticals | SCHEDULE 13G/A: Others - Moomoo
Millennium group reports shared control of 1.9M KalVista shares (KALV) - Stock Titan
KALV Downgraded by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
KalVista Pharmaceuticals 2025 Executive Compensation, Equity Awards, and Corporate Governance Highlights - Minichart
KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc.KALV - Business Wire
H.C. Wainwright Downgrades KalVista Pharmaceuticals(KALV.US) to Hold Rating, Cuts Target Price to $27 - Moomoo
KalVista Pharmaceuticals (NASDAQ:KALV) Rating Lowered to "Neutral" at HC Wainwright - MarketBeat
Kalvista Pharmaceuticals stock rating cut to neutral by H.C. Wainwright on merger deal - Investing.com Nigeria
KalVista Pharmaceuticals (NASDAQ:KALV) Stock Rating Lowered by JonesTrading - MarketBeat
KalVista Pharmaceuticals (NASDAQ:KALV) Downgraded by Leerink Partners to Hold - MarketBeat
KalVista Pharmaceuticals (NASDAQ:KALV) Downgraded by Citizens Jmp to Hold - MarketBeat
Needham Downgrades KalVista Pharmaceuticals(KALV.US) to Hold Rating - Moomoo
KalVista Pharmaceuticals | 10-KT/A: Others - Moomoo
IBT portfolio manager says KalVista deal signals Biotech 2.0 growth - Proactive financial news
Chiesi widens rare disease portfolio with $1.9bn KalVista buyout - MSN
KalVista (NASDAQ: KALV) amends 10-KT, reveals April 29, 2026 merger deal with Chiesi - Stock Titan
KALV Downgraded by Needham -- Rating Changed to Hold - GuruFocus
KalVista Pharmaceuticals (NASDAQ:KALV) Given "Hold" Rating at Needham & Company LLC - MarketBeat
Hereditary Angioedema Market: Rapid Increment Driven by Innovation by 2034DelveInsight - openPR.com
KalVista Pharmaceuticals (NASDAQ:KALV) Sees Large Volume IncreaseHere's Why - MarketBeat
Chiesi commits $1.9bn to rare disease expansion with KalVista Buy - BioXconomy
Jones Trading downgrades Kalvista stock to hold on Chiesi acquisition By Investing.com - Investing.com South Africa
Jones Trading downgrades Kalvista stock to hold on Chiesi acquisition - Investing.com
Italy: Chiesi Group expanding global Rare Disease portfolio with US$1.9bn acquisition of KalVista - Investors in Healthcare
Shorted-to-The-Hilt KalVista Rockets 39% as Chiesi Swoops in With $1.9bn Cash Bid - NAI500
Leerink Partners Downgrades KalVista Pharmaceuticals(KALV.US) to Hold Rating, Announces Target Price $27 - Moomoo
KalVista Downgraded to $27 Target as Chiesi’s All-Cash Takeout Caps Near-Term Upside, Supporting Hold Rating - TipRanks
Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio - 투데이안
JonesTrading Downgrades KalVista Pharmaceuticals(KALV.US) to Hold Rating, Cuts Target Price to $27 - Moomoo
DRI Healthcare Trust Evaluates Royalty Agreement With KalVista After Chiesi Deal Proposal - Moomoo
Stock Market Today, April 29: KalVista Pharmaceuticals Surges on Chiesi Group Acquisition Announcement - The Motley Fool
KalVista Pharmaceuticals | SC14D9C: Written communication by the subject company relating to a third party tender offermoomoo - Moomoo
Chiesi Grows Again In Rare Diseases With Its Largest Deal Yet, Buying KalVista - Citeline News & Insights
Sector Update: Health Care Stocks Fall Late Afternoon - Moomoo
Chiesi to acquire KalVista Pharmaceuticals for $1.9 billion By Investing.com - Investing.com Australia
DRI Healthcare Trust Comments on Proposed Acquisition of KalVista Therapeutics, Inc. - Newswire Canada
Biotech Scores $1.9 Billion Deal; Why A Key Rival Also Jumped - Investor's Business Daily
Deal And Earnings Wins Powered A Big Day For Three Stocks - Finimize
Italian drugmaker Chiesi to buy KalVista for $1.9 billion - Classic Rock 103.5 WIMZ
CPI | Italian Drugmaker to Buy KalVista for $1.9 Billion - PYMNTS.com
Chiesi Group Grows Again in Rare Disease With $1.9B KalVista Acquisition - MedCity News
KalVista (KALV) Receives No Rating Following Acquisition Announcement - GuruFocus
Regeneron Pharmaceuticals Inc Stock (REGN) Moved Down by 7.82% on Apr 29: Facts Behind the Movement - TradingKey
KALV Stock Alert: Halper Sadeh LLC is Investigating Whether KalVista Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders - Business Wire
KalVista moved to No Rating at BofA - TipRanks
Kalvista Pharmaceuticals Inc (KALV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.48%
자본화:
|
볼륨(24시간):